Comparative Pharmacology
Head-to-head clinical analysis: VOLTAREN XR versus XIBROM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: VOLTAREN XR versus XIBROM.
VOLTAREN-XR vs XIBROM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis. This leads to anti-inflammatory, analgesic, and antipyretic effects.
XIBROM (bromfenac) is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis, thereby decreasing intraocular inflammation.
100 mg orally once daily, extended-release formulation. Maximum 150 mg/day (divided as 75 mg twice daily or 100 mg once daily).
Instill 1 drop into the affected eye(s) 4 times daily starting 24 hours before surgery and continuing for 2 weeks postoperatively.
None Documented
None Documented
The terminal elimination half-life is approximately 2 hours. The extended-release formulation (XR) does not alter the half-life; it maintains prolonged therapeutic plasma concentrations with twice-daily dosing.
Terminal elimination half-life is approximately 42 hours. Clinical context: Due to its long half-life, steady-state is achieved after about 8 days of daily dosing, which contributes to sustained anti-inflammatory effect.
Approximately 65% of a dose is excreted renally as unchanged drug and metabolites (primarily as glucuronide conjugates); about 35% is eliminated via bile in feces.
Renal: ~70% (primarily as unchanged drug); Biliary/Fecal: ~15% (as metabolites); the remainder is eliminated via other minor pathways.
Category C
Category C
NSAID
NSAID